The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): Comparison

Neurochemical Research

Volumn 38, Issue 7, 2013, Pages 1490-1495

  Dietrich Muszalska, Anna ^a   Kopka, Justyna ^a   Kwiatkowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antipsychotics; Clozapine; Haloperidol; Lipid peroxidation; Oxidative stress; Ziprasidone

Indexed keywords

CLOZAPINE; HALOPERIDOL; LIPID; NEUROLEPTIC AGENT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ZIPRASIDONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHIZOPHRENIA; SPECTROPHOTOMETRY;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; LIPID PEROXIDATION; MALE; PIPERAZINES; THIAZOLES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84878889333     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1050-z     Document Type: Article

References (41)

1. Al-Chalabi BM, Thanoon IA, Ahmed FA (2009) Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 59(1):8-11
2. Akyol O, Herken H, Uz E, Fadillioǧlu E, Unal S, Söǧüt S et al (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 26:995-1005
3. Bartosz G (2003) Total antioxidant capacity. Adv Clin Chem 37:219-292
4. Cadet JL, Lohr JB (1987) Free radicals and the developmental pathobiology of schizophrenic burnout. Integr Psychiatry 5:40-48
5. Cadet JL, Perumal AS (1990) Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 28:738-740
6. Cadet JL, Lohr JB, Jeste DV (1986) Free radicals and tardive dyskinesia. Trends Neurosci 9:107-108
7. Dadheech G, Mishra S, Gautam S, Sharma P (2008) Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 50(1):16-20
8. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A (2004) Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49(4):205-209
9. Dalla Libera A, Rigobello MP, Bindoli A (1996) Inhibitory action of neuroleptic drugs and serotonin on dopamine autooxidation and lipid peroxidation. Prog Neuropsychopharmacol Biol Psychiatry 19:291-298
10. Dalla Libera A, Scutari G, Boscolo R, Rigobello MP, Bindoli A (1998) Antioxidant properties of clozapine and related neuroleptics. Free Radic Res 29(2):151-157
11. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J (2005) Oxidative stress in blood platelets from schizophrenic patients. Platelets 16(7):386-391
12. Dietrich-Muszalska A, Kontek B, Rabe-Jablonska J (2011) Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro. Neuropsychobiology 63:197-201
13. Dietrich-Muszalska A, Olas B (2007) Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 14:1-6
14. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ (2005) WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132-191
15. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ (2006) WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term of schizophrenia. World J Biol Psychiatry 7:5-40
16. Fischer V, Haar JA, Greiner L, Lioyd RV, Mason RP (1991) Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Mol Pharmacol 40:846-853
17. Gama CS, Salvador M, Andreazza AC, Kapczinski F, Belmonte-de-Abreu PS (2006) Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 30:512-515
18. Horrobin DF (1996) Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 55:3-7
19. Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Arunoma OI et al (1995) Characterisation of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 49:359-365
20. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (2002) Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58(1):1-10
21. Khan NS, Das I (1997) Oxidative stress and superoxide dismutase in schizophrenia. Biochem Soc Trans 25:418
22. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J et al (2005) Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsych 17:227-231
23. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV (1990) Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 28(6):535-539
24. Mahadik SP, Evans DR (2003) Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 26(1):85-102
25. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79-104
26. Möller HJ (2004) Novel antipsychotics in the long-term treatment of schizophrenia. World J Biol Psychiatry 5:9-19
27. Padurariu M, Ciobica A, Dobrin I, Stefanescu C (2010) Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479(3):317-320
28. Pai BN, Janakiramaiah N, Gangadhar BN, Ravindranath V (1994) Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 36:489-491
29. Pall HS, Williams AC, Blake DR, Lunec J (1987) Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 2:596-599
30. Parikh V, Khan MM, Mahadik SP (2003) Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37:43-51
31. Peet M, Laugharne J, Rangarajan N, Reynolds GP (1993) Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychophamacol 8:151-153
32. Pillai A, Parikh V, Terry AV Jr, Mahadik SP (2007) Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 41(5):372-386
33. Rice-Evans CA (1994) Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: Rice-Evans CA, Burdone RH (eds) Free radical damage and its control. Elsevier, Amsterdam, pp 131-153
34. Sagara Y (1998) Induction of reactive oxygen species in neurones by haloperidol. J Neurochem 71(3):1002-1012
35. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33
36. Shivakumar BR, Ravindranath V (1993) Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 265(3):1137-1141
37. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT (1998) Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 155:1207-1213
38. Yao JK, Keshavan MS (2011) Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 15(7):2011-2035
39. Yao JK, Reddy RD, van Kammen DP (2001) Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15(4):287-310
40. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y et al (2006) Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 81(2-3):291-300
41. Zhang M, Zhao Z, He L, Wan C (2010) A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 53(1):112-124